Form 4: AtriCure COO Douglas J. Seith Acquires Shares Through Employee Stock Purchase Plan
SEC Form 4 Filing
Douglas J. Seith, Chief Operating Officer of AtriCure, Inc., acquired 707 shares of common stock through the company's Employee Stock Purchase Plan at a price of $19.35 per share.
Summary
- On June 28, 2024, Douglas J. Seith, the Chief Operating Officer of AtriCure, Inc., acquired 707 shares of the company's common stock.
- The acquisition was made through the AtriCure, Inc. 2018 Employee Stock Purchase Plan (ESPP) for the period ending June 30, 2024.
- The price per share was $19.35, which represents 85% of the closing price of AtriCure's common stock on June 28, 2024 ($22.77).
- Following the transaction, Seith directly owns 154,227 shares of AtriCure, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating an insider transaction through an employee stock purchase plan. There's no indication of significant positive or negative implications.
Positives
- The acquisition of shares by a key executive like the COO can be seen as a positive signal, indicating confidence in the company's future performance.
- The ESPP allows employees to purchase shares at a discounted rate, aligning their interests with those of the shareholders.
Industry Context
This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency regarding the ownership positions of key executives.
Comparison to Industry Standards
- Employee Stock Purchase Plans are a common benefit offered by many publicly traded companies, including those in the medical device industry.
- The discount of 15% from the market price offered through AtriCure's ESPP is within the typical range for such plans.
- Similar filings are regularly made by executives at comparable companies like Medtronic, Boston Scientific, and Abbott Laboratories, reflecting their participation in company stock plans or open market transactions.
Stakeholder Impact
- The transaction has a minor positive impact on employee morale as it demonstrates the availability of employee benefits such as the ESPP.
- The transaction has a negligible impact on shareholders as it is a small number of shares compared to the total outstanding.
Key Dates
| Date | Description |
|---|---|
| 06/28/2024 | Date of the transaction: Douglas J. Seith acquired 707 shares of AtriCure common stock. |
| 06/28/2024 | Last trading day of the ESPP offering period; closing price of AtriCure common stock was $22.77. |
| 06/30/2024 | End of the period for the AtriCure, Inc. 2018 Employee Stock Purchase Plan. |
| 07/02/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.